XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 81.88

Change

+0.51 (+0.63)%

Market Cap

N/A

Volume

9.30M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.68 (+0.49%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.42 (+0.65%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+0.96 (+0.97%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+0.38 (+0.48%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.02 (-0.10%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+0.69 (+0.72%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.29 (+1.00%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.18 (+0.67%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.41 (+0.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.13 (+0.70%)

USD 0.01B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

-0.10 (0%)

USD 0.06B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.08% 19% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.08% 19% F 25% F
Trailing 12 Months  
Capital Gain -3.24% 24% F 33% F
Dividend Return 0.15% 19% F 2% F
Total Return -3.08% 24% F 27% F
Trailing 5 Years  
Capital Gain -12.32% 19% F 24% F
Dividend Return 0.50% 26% F 1% F
Total Return -11.82% 19% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -6.99% 14% F 10% F
Dividend Return -6.92% 14% F 8% B-
Total Return 0.06% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 24.56% 19% F 41% F
Risk Adjusted Return -28.18% 14% F 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.